- Home
- BDSX
BDSX
Biodesix Inc.
as 07-26-2024 4:00pm EST
Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Coronavirus Disease 2019 (COVID-19) tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | BOULDER |
| Market Cap: | 175.5M | IPO Year: | 2020 |
| Target Price: | $3.15 | AVG Volume (30 days): | 151.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.54 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.03 - $2.21 | Next Earning Date: | 08-05-2024 |
| Revenue: | $54,849,000 | Revenue Growth: | 34.70% |
| Revenue Growth (this year): | 38.75% | Revenue Growth (next year): | 23.98% |
Stock Insider Trading Activity of Biodesix Inc. (BDSX)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| O'Kane Kieran | BDSX | Chief Commercial Officer | May 8 '24 | Sell | $1.48 | 468 | $692.41 | 75,524 | SEC Form 4 |
| Hutton Scott | BDSX | President & CEO | May 8 '24 | Sell | $1.48 | 3,764 | $5,568.84 | 483,780 | SEC Form 4 |
| Vazquez Chris | BDSX | Chief Accounting Officer | May 8 '24 | Sell | $1.48 | 244 | $361.00 | 9,915 | SEC Form 4 |
| Pestano Gary Anthony | BDSX | Chief Development Officer | May 8 '24 | Sell | $1.48 | 434 | $642.10 | 124,248 | SEC Form 4 |
| Cowie Robin Harper | BDSX | CFO, Sec'y & Treasurer | May 8 '24 | Sell | $1.48 | 980 | $1,449.91 | 171,680 | SEC Form 4 |
| Vazquez Chris | BDSX | Chief Accounting Officer | Feb 8 '24 | Sell | $1.92 | 1,077 | $2,064.18 | 10,470 | SEC Form 4 |
| Vazquez Chris | BDSX | Chief Accounting Officer | Feb 8 '24 | Sell | $1.66 | 922 | $1,534.85 | 9,548 | SEC Form 4 |
| Pestano Gary Anthony | BDSX | Chief Development Officer | Feb 8 '24 | Sell | $1.92 | 5,862 | $11,235.11 | 128,272 | SEC Form 4 |
| Pestano Gary Anthony | BDSX | Chief Development Officer | Feb 8 '24 | Sell | $1.66 | 5,022 | $8,360.12 | 123,250 | SEC Form 4 |
| O'Kane Kieran | BDSX | Chief Commercial Officer | Feb 8 '24 | Sell | $1.92 | 6,319 | $12,111.00 | 73,417 | SEC Form 4 |
| O'Kane Kieran | BDSX | Chief Commercial Officer | Feb 8 '24 | Sell | $1.66 | 5,412 | $9,009.36 | 68,005 | SEC Form 4 |
| Cowie Robin Harper | BDSX | CFO, Sec'y & Treasurer | Feb 8 '24 | Sell | $1.92 | 10,156 | $19,464.99 | 178,109 | SEC Form 4 |
| Cowie Robin Harper | BDSX | CFO, Sec'y & Treasurer | Feb 8 '24 | Sell | $1.66 | 8,699 | $14,481.23 | 169,410 | SEC Form 4 |
| Hutton Scott | BDSX | President & CEO | Feb 8 '24 | Sell | $1.92 | 34,682 | $66,471.52 | 494,719 | SEC Form 4 |
| Hutton Scott | BDSX | President & CEO | Feb 8 '24 | Sell | $1.66 | 29,708 | $49,454.91 | 465,011 | SEC Form 4 |
Latest Biodesix Inc. News
BDSX Breaking Stock News: Dive into BDSX Ticker-Specific Updates for Smart Investing
Business Wire
3 days ago
Biodesix to Report Second Quarter 2024 Financial Results on August 7, 2024
Simply Wall St.
15 days ago
This Biodesix Insider Increased Their Holding In The Last Year
Business Wire
a month ago
Biodesix Named to Inc. Magazine’s 2024 "Best Workplaces"
Business Wire
2 months ago
Biodesix to Participate in Two Investor Conferences in June
Business Wire
2 months ago
Biodesix to Present New Data on the Nodify XL2® Test at ATS 2024 Annual Meeting
Simply Wall St.
3 months ago
Biodesix, Inc. (NASDAQ:BDSX) Just Reported Earnings, And Analysts Cut Their Target Price
Insider Monkey
3 months ago
Biodesix, Inc. (NASDAQ:BDSX) Q1 2024 Earnings Call Transcript
GuruFocus.com
3 months ago
Biodesix Inc (BDSX) Surpasses Analyst Revenue Forecasts with Strong Q1 2024 Performance
Compare BDSX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BDSX Biodesix Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.